Evidence map›Paper›PMID 36962909›Full record

ArticlePLOS global public health2022

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.

Sedona Sweeney, Catherine Berry, Emil Kazounis, Ilaria Motta, Anna Vassall, Matthew Dodd, Katherine Fielding, Bern-Thomas Nyang'wa

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
3.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Treatment of Drug-Resistant Tuberculosis with Bedaquiline, Pretomanid, Linezolid with or Without Moxifloxacin (BPaL/M): Feasibility and Implementation Challenges in Western Canada.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Sedona SweeneyFaculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0003-4233-9080
Catherine BerryPublic Health Department OCA, Médecins Sans Frontières, London, United Kingdom.
Emil KazounisPublic Health Department OCA, Médecins Sans Frontières, London, United Kingdom.
Ilaria MottaPublic Health Department OCA, Médecins Sans Frontières, London, United Kingdom.
Anna VassallFaculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Matthew DoddFaculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Katherine FieldingFaculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Bern-Thomas Nyang'waPublic Health Department OCA, Médecins Sans Frontières, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9915-5878
London School of Hygiene & Tropical Medicine · GBMédecins Sans Frontières‎ · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimate the incremental cost-effectiveness of three regimens containing bedaquiline, pretomanid and linezolid (BPaL) with and without moxifloxacin (BPaLM) or clofazimine (BPaLC) compared with the current mix of long and short standard of care (SOC) regimens to treat RR-TB from the provider perspective in India, Georgia, Philippines, and South Africa. We estimated total costs (2019 USD) and disability-adjusted life years (DALYs) over a 20-year time horizon. Costs and DALYs were discounted at 3% in the base case. Parameter uncertainty was tested with univariate and probabilistic sensitivity analysis. We found that all three regimens would improve health outcomes and reduce costs compared with the current programmatic mix of long and short SOC regimens in all four countries. BPaL was the most cost-saving regimen in all countries, saving $112-$1,173 per person. BPaLM was the preferred regimen at a willingness to pay per DALY of 0.5 GDP per capita in all settings. Our findings indicate BPaL-based regimens are likely to be cost-saving and more effective than the current standard of care in a range of settings. Countries should consider programmatic uptake of BPaL-based regimens.

Identifiers

PMID36962909
PMCPMC10022130
OpenAlexW4311829650

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read56
identifiers read5
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.